Gold nanoparticle interactions in human blood: a model evaluation
journal contributionposted on 2018-12-06, 11:39 authored by Niloofar Ajdari, Cian Vyas, Stephanie L. Bogan, Bashir A. Lwaleed, Brian Cousins
In this study, we investigated gold nanoparticle (AuNP) interactions in blood using thromboelastography as a rapid screening tool to monitor their influence on blood coagulation. 1.2 nM colloidal AuNPs ranging from 12 to 85 nm have no effect in the blood, however, 5 nM AuNPs demonstrate pro-thrombogenic concentration dependent effects with a reduction in clot formation. Size effects exhibit a non-linear trend with 45 and 85 nm particles resulting in a faster pro-thrombotic response. Clot strength decreased with AuNP size with the greatest reduction with 28 nm particles. We assessed AuNP interactions in the blood focusing on their biological activity. AuNP-RGD possessed procoagulant activities, while PEG-thiol, human fibrinogen and clopidogrel prevented blood clot formation and influenced platelet activity, and were more efficient when bound to nanocarriers than unbound ligands. Such tests could fill the knowledge gaps in thrombogenicity of NPs between in vitro test methods and predict in vivo haemocompatibility.
The authors would like to acknowledge the financial support of the EPSRC CASE Award (EP/ L504889/1), and Healthcare Impact Partnership (EP/L024713/1).
Published inNanomedicine: Nanotechnology, Biology and Medicine
Pages1531 - 1542
CitationAJDARI, N. ... et al., 2017. Gold nanoparticle interactions in human blood: a model evaluation. Nanomedicine: Nanotechnology, Biology and Medicine, 13(4), pp. 1531-1542.
Publisher© the Authors. Published by Elsevier
- VoR (Version of Record)
Publisher statementThis work is made available according to the conditions of the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Full details of this licence are available at: http://creativecommons.org/licenses/ by/4.0/
NotesThis is an Open Access Article. It is published by Elsevier under the Creative Commons Attribution 4.0 Unported Licence (CC BY). Full details of this licence are available at: http://creativecommons.org/licenses/by/4.0/